A 28-year-old woman from Delhi presents with jaundice, malaise, and right upper quadrant pain for 10 days. She is a healthcare worker with a needle-stick injury 6 weeks ago. Serology: HBsAg positive, anti-HBc IgM positive, HBeAg positive, HBV DNA 8.5 × 10⁶ IU/mL. ALT 3200 U/L, AST 2800 U/L, bilirubin 9.1 mg/dL, INR 1.2, albumin 3.6 g/dL. What is the most appropriate next step in management?

Explanation

## Clinical Scenario Analysis This patient has **acute hepatitis B** with: - **Occupational exposure** (needle-stick 6 weeks prior; incubation 45–180 days) - **Anti-HBc IgM positive** (diagnostic of acute HBV infection) - HBsAg and HBeAg positive, high viral load (8.5 × 10⁶ IU/mL) - **Preserved synthetic function** (INR 1.2, albumin 3.6 g/dL) - Marked transaminitis but no signs of fulminant failure ## Management of Acute Hepatitis B **Key Point:** Acute hepatitis B in immunocompetent adults is **self-limited** in 90–95% of cases. **Antiviral therapy is NOT routinely indicated** in acute HBV unless there are signs of **fulminant hepatic failure** (FHF) or severe hepatic decompensation. **High-Yield:** The distinction between acute and chronic HBV infection is critical: - **Acute HBV:** Anti-HBc IgM positive (this patient) → most will clear infection spontaneously - **Chronic HBV:** Anti-HBc IgG positive, anti-HBc IgM negative → requires long-term antiviral therapy ### Criteria for Antiviral Therapy in Acute HBV Antiviral therapy (tenofovir or entecavir) is indicated ONLY if: 1. **INR >1.5** (indicates significant coagulopathy/synthetic dysfunction) 2. **Encephalopathy** (hepatic encephalopathy grade ≥1) 3. **Fulminant hepatic failure** (rapid deterioration, bilirubin >20 mg/dL with INR >1.5) 4. **Immunocompromised state** (HIV, transplant, etc.) 5. **Age >40 years** with severe acute hepatitis This patient has **none of these criteria**. ### Management Strategy | Step | Rationale | |------|----------| | **Admission** | Daily INR and bilirubin monitoring; low threshold for detecting FHF | | **Supportive care** | IV hydration, electrolyte correction, nutritional support, rest | | **Avoid hepatotoxins** | Alcohol, acetaminophen, NSAIDs | | **Monitor INR daily** | If INR rises >1.5, initiate antiviral therapy (tenofovir 300 mg daily) | | **Recheck serology at 3 months** | Anti-HBs seroconversion indicates recovery; HBsAg persistence >6 months = chronic HBV | **Clinical Pearl:** Most patients with acute HBV clear HBsAg within 6 months and develop anti-HBs (protective antibody). Starting antivirals in the acute phase in non-fulminant cases does NOT improve outcomes and may delay immune clearance. ## Why Each Option Is Correct or Wrong **Correct Answer: Admit for supportive care and daily INR monitoring; initiate antiviral therapy only if INR rises above 1.5 or encephalopathy develops** - Respects the self-limited nature of acute HBV in immunocompetent hosts - Allows early detection of fulminant failure (INR >1.5 is a key trigger) - Avoids unnecessary antiviral therapy in a patient likely to recover spontaneously **Why "Start tenofovir immediately" is wrong:** - Acute HBV does not require immediate antiviral therapy unless fulminant features are present - This patient has preserved synthetic function (INR 1.2) — no indication for antivirals now - Premature antiviral initiation may interfere with immune clearance and increase risk of chronic infection **Why "Refer for urgent liver transplant evaluation" is wrong:** - Transplant is reserved for **fulminant hepatic failure** with encephalopathy and INR >1.5 that does not improve with medical management - This patient has no encephalopathy and normal INR — too early for transplant consideration - Prognosis is excellent with supportive care alone **Why "Perform liver biopsy" is wrong:** - Biopsy is contraindicated in acute hepatitis with potential coagulopathy (INR 1.2 is borderline) - Diagnosis is confirmed by serology (anti-HBc IgM); biopsy adds no diagnostic value - Histology does not change acute HBV management in non-fulminant cases **Mnemonic: "SAFE-B"** — **S**elf-limited acute HBV, **A**dmit for monitoring, **F**ulminant features trigger antivirals, **E**xpect recovery; **B**ased on INR trend. [cite:Harrison 21e Ch 297]